

Ref. No.: EIKO/BSE/2023-24/37

Date: 08th November 2023

To, Corporate Services Department, **BSE Limited**, P J Towers, 1st Floor, Dalal Street, Fort, Mumbai - 400001.

Scrip Code: 540204

Sub: Nil Statement of Deviation(s) or Variation(s) under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam

Please find enclosed herewith Annexure- I the Statement of Deviation(s) or Variation(s) under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, for the quarter ended September 30, 2023 duly reviewed by the Audit Committee at its meeting held on November 08, 2023

We hereby confirm that there has been no deviation or variation in the use of proceeds of funds raised through Right Issue.

Kindly take the same on your records.

Thanking you,

For **EIKO LIFESCIENCES LIMITED**

Jaid Kojar Chief Financial Officer

Encl: Annexure I



Annexure I

Statement of Deviation / Variation in utilisation of funds raised	
Name of listed entity	Eiko Lifesciences Limited
Mode of Fund Raising	Right Issue
Date of Raising Funds (Date of Allotment)	2 nd August 2023
Amount Raised	₹7,48,46,403
Report filed for Quarter ended	30-09-2023
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	Not Applicable
Comments of the auditors, if any	Not Applicable
Objects for which funds have been raised and where there has been a deviation, in the following table	Not Applicable